Noticias

• Developed by Navarrabiomed's Childhood and Adolescent Physical Activity Research Unit

The Diactive-1 project, led by the Childhood and Adolescent Physical Activity Research Unit at Navarrabiomed in collaboration with the Navarra University Hospital (HUN/NOU), ANADI, and managed through IdiSNA, has been awarded the ITEMAS-ISCIII Quality Seal. This recognition endorses its scientific and technical quality, level of maturity, and transfer potential as an innovative digital health solution.

Diactive-1 stems from a well-established line of research developed through projects funded by the Carlos III Health Institute (PI21/01238), focused on improving the safety, personalization, and effectiveness of physical exercise among children and adolescents with type 1 diabetes.

The project has been materialized as a mobile application designed to facilitate safe physical activity tailored to each user's needs. The tool provides personalized strength training programs, therapeutic education content, and recommendations aimed at maintaining glucose stability during exercise. Its goal is to support the integration of physical activity into disease management and contribute to improving the health and quality of life of children and adolescents living with type 1 diabetes.

Recognition of its transfer potential

According to the evaluation report, Diactive-1 addresses a significant clinical need and demonstrates strong potential for implementation within Spain's National Health System. The report also highlights the advanced stage of development achieved by the project and its capacity to progress toward future validation and implementation phases.

One of its key strengths is its current presence in 11 hospitals (PI24/00829), which facilitates the generation of evidence in real-world clinical settings and supports its future incorporation into routine healthcare practice.

"Receiving the ITEMAS-ISCIII Quality Seal is a major endorsement for Diactive-1 because it recognizes not only the project's scientific and technological quality, but also its transfer potential and possible impact on clinical practice," said Antonio García-Hermoso, Principal Investigator of the project and Associate Professor at the Public University of Navarra (UPNA).

Promoting technology valorization

The achievement of this recognition has been made possible through the joint efforts of the research team and Navarrabiomed's Scientific-Technical Innovation Service, which has supported the project's maturation process and the development of its transfer strategy. As part of this process, Diactive-1 has registered its trademark (No. 019322598), strengthening its identity and positioning as an innovative digital solution for pediatric type 1 diabetes management in individuals aged 8 to 18 years.

"This recognition highlights the importance of addressing technology transfer from the very early stages of research projects. In the case of Diactive-1, an accompanying process has enabled us to consolidate its value proposition, define its protection strategy, and prepare a competitive application for the ITEMAS-ISCIII Quality Seal," explained Beatriz Pérez, Head of Navarrabiomed's Scientific-Technical Innovation Service.

Research aimed at making an impact

With this distinction, Diactive-1 further strengthens its position as a digital solution designed to address a real clinical need and with the potential for integration into the healthcare system. The project combines scientific evidence, clinical expertise, and technology to promote safer and more personalized physical exercise among children and adolescents with type 1 diabetes. "This is a step toward helping young people with type 1 diabetes feel a little freer," said Ignacio Hormazabal and Jacinto Muñoz, researchers involved in the project.

The award of the ITEMAS-ISCIII Quality Seal also incorporates Diactive-1 into a national network of innovative initiatives with potential application in the healthcare system. Navarrabiomed is part of ITEMAS as an associated entity, a platform of the Carlos III Health Institute (ISCIII) that promotes healthcare innovation and technology transfer through a network comprising more than one hundred hospitals, institutes, and research centers. This collaboration supports the development, validation, and adoption of innovations designed to address the real needs of patients and healthcare professionals, helping projects such as Diactive-1 advance toward practical implementation within the healthcare system.

• Navarrabiomed has led this initiative, which promotes brain immunomodulation strategies to preserve and improve cognitive and motor functions

  ---

   

The INNOLFACT 2.0 project, led by Navarrabiomed and carried out by the Navarra University Hospital (HUN), CIMA, the University of Navarra, ADItech Foundation, and the companies Eversens and NNBI 2020, has concluded with highly significant results in the field of precision medicine applied to neurodegenerative diseases. The Department of Industry and of Ecological and Digital Business Transition awarded €1.6 million in funding through the 2023-2026 Strategic Projects Call for the second phase of INNOLFACT, enabling the consolidation of an innovative approach that connects the olfactory system, the immune system, and cognition.

INNOLFACT 2.0, led by Enrique Santamaría, Principal Investigator of the Clinical Neuroproteomics Unit at Navarrabiomed, and Ana María García-Osta, Co-Principal Investigator of the project and researcher in the Neurological Disease Gene Therapy Program at CIMA University of Navarra, has consolidated a translational research model focused on the olfactory-immune-brain axis, with direct applications in neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. Developed by a multidisciplinary consortium, INNOLFACT 2.0 has promoted the implementation of Olfactory Precision Medicine, an innovative approach that positions the olfactory system as a key tool both for the early diagnosis of neurodegenerative diseases and for the development of new therapeutic strategies.

The INNOLFACT 2.0 project is co-funded by the European Regional Development Fund (ERDF) through Navarra’s ERDF 2021-2027 Programme, and by the Government of Navarra under the 2023-2026 Strategic R&D Projects Call, with total funding of €1.6 million. The project has been part of the SIBERIA Challenge, which focuses on finding innovative biotechnology solutions. Since 2019, the Department of Industry and of Ecological and Digital Business Transition has already funded 13 projects in this field.

The project has achieved its scientific and collaborative objectives, demonstrating a clear interaction between the olfactory, immune, and cognitive systems, and establishing a solid framework for future initiatives in the field of neurodegeneration. Through INNOLFACT 2.0, Navarra reaffirms its commitment to research excellence and advances towards a model in which the olfactory pathway becomes a relevant tool for anticipating and understanding the progression of complex diseases.

Olfaction as a biomarker and intervention pathway

The project has highlighted the value of olfaction as an early indicator of neurodegeneration, as well as its close relationship with immune processes involved in the progression of neurodegenerative diseases. In this context, INNOLFACT 2.0 has generated new knowledge on the mechanisms linking olfactory function with the immune response and the central nervous system. The project has advanced the identification of olfactory, immunological, and molecular biomarkers associated with Alzheimer’s and Parkinson’s diseases, while also developing intranasal delivery systems for repurposed drugs that have successfully passed the initial validation stages in animal models.
Furthermore, the project has enabled the integration of clinical, sensory, and omics data to improve patient stratification and early diagnosis, incorporating artificial intelligence and machine learning tools to support disease prediction and classification in clinical settings.

Therapeutic innovation: from diagnosis to intervention

One of the most distinctive aspects of the project has been its exploration of the olfactory system not only as a diagnostic tool but also as a potential therapeutic route. In this regard, INNOLFACT 2.0 has laid the groundwork for the development of intranasal therapies targeting the central nervous system, taking advantage of the direct connection between the olfactory pathway and the brain.
In addition, the project has promoted the study of brain immunomodulation strategies aimed at preserving or improving cognitive and motor functions, as well as the application of olfactory training as a potential sensory intervention tool with clinical impact.

A high-level multidisciplinary consortium

INNOLFACT 2.0 has consolidated a collaborative ecosystem that integrates biomedical research, clinical practice, and technological development. This ecosystem is structured around a consortium bringing together the capabilities of Navarrabiomed, the Navarra University Hospital, the University of Navarra Clinic, CIMA, and the University of Navarra, with expertise in proteomics, geriatrics, neurology, otorhinolaryngology, neurobiology, immunology, bioinformatics, engineering, and data analysis.

The project also includes a strong knowledge-transfer component through the participation of the Navarre-based companies NNBi, focused on predictive algorithm development and healthcare digitalization, and Eversens, which specializes in the development of non-invasive medical devices for monitoring biomarkers in exhaled breath. Furthermore, with the methodological support of ADItech, coordinator of the Navarra R&D&I System (SINAI), a gender perspective has been integrated throughout all stages of the project, following evidence of sex-related differences in neurodegenerative diseases.

In line with the vision set out by the project, INNOLFACT 2.0 lays the foundations for further integrating olfaction into the clinical management of neurodegenerative diseases and aging, with the goal of improving early detection and exploring new therapeutic approaches focused on maintaining the proper functioning of the olfactory-immune-brain axis.

The deadline for submitting proposals is 31 August 2026. 

The European project THERESA PCP, coordinated by Navarrabiomed-Miguel Servet Foundation, has officially launched its call for tenders with the aim of promoting the development of innovative technologies for hospital wastewater treatment. The call has an estimated total budget of up to €2.9 million to support solutions from their design phase through to validation in real-world conditions and is funded by the Horizon Europe programme. 

A three-phase pre-commercial procurement process

The procurement is structured as a competitive process in three phases, characteristic of the PCP model, which allows for the progressive development of the proposed solutions-from initial concept design to validation in real operating environments:
•    Phase 1 (solution design): up to €20,000 per contractor, with a maximum of five selected proposals.
•    Phase 2 (prototype development): up to €500,000 per contractor, with a maximum of three selected.
•    Phase 3 (validation and demonstration): up to €450,000 per contractor, with a maximum of two participants. 

Call open to innovative companies and organisations

The call is addressed to companies, SMEs, startups and technological consortia developing innovative solutions in the field of hospital wastewater treatment. The project aims to attract proposals that contribute to reducing the environmental impact of these effluents, as well as mitigating associated risks such as the presence of pharmaceutical contaminants or resistant microorganisms. 

Interested entities must follow a participation process that includes downloading the tender documentation, preparing the proposal-with the possibility to submit questions and establish collaborations through a matchmaking platform-and the final submission of the offer. 

Online information session

To facilitate participation and address potential questions, an online information session to present the tender documents will take place on 17 June at 10:00 (CEST). During this session, the details of the process will be explained and any questions raised by participants will be addressed. 

All interested organisations are encouraged to attend this session, which is intended as a key opportunity to better understand the requirements of the call and support proposal preparation. 

Registration for the information session: Registration form for the online session. 

Deadline and access to the tender: The deadline for submitting proposals is 31 August 2026. 

Additional information:

• Tender notice in the Official Journal of the European Union.
• Project website and full documentation.
• Submission platform.
• Matchmaking platform to identify partners.

This innovative preclinical study specifically destroys the chromosome of Staphylococcus aureus, one of the world’s most dangerous and antibiotic-resistant bacteria.

The Microbial Pathogenesis Unit at Navarrabiomed-UPNA has developed an innovative antimicrobial strategy capable of eliminating infections caused by Staphylococcus aureus, a bacterium associated with more than one million deaths worldwide each year. The innovation, currently at the preclinical stage, is based on the genetic modification of viruses to act as “Trojan horses,” entering exclusively into Staphylococcus aureus cells and destroying them from within, without affecting the other microorganisms that make up the body’s microbiota.

The research, published in npj Biofilms and Microbiomes and funded by the Spanish Ministry of Science, Innovation and Universities, involved multidisciplinary work combining molecular microbiology, synthetic biology, and experimental mouse infection models. The study was led by Dr. Íñigo Lasa, Principal Investigator of the Microbial Pathogenesis Unit at Navarrabiomed and Professor at the Public University of Navarra (UPNA). The work was carried out primarily by Nahiara Garmendia-Antoñana and Pedro Dorado-Morales, with the collaboration of José R. Penadés, Head of the Department of Infectious Disease at Imperial College London.

Research Impact

Staphylococcus aureus is a very common bacterium that colonizes the skin and nasal passages of approximately 30% of the adult population. However, once it breaches the epithelial barrier, it becomes an extraordinarily versatile pathogen. For this reason, the international scientific community is engaged in a race against time to develop precision antimicrobials capable of effectively targeting it.

The Navarrabiomed study uses synthetically engineered bacteriophages, viruses that specifically infect Staphylococcus aureus. These viruses carry the CRISPR gene-editing system, acting as molecular scissors programmed to cut the genetic material of the bacterium. The viruses are completely harmless to humans because they are unable to infect human cells. To date, the therapy’s effectiveness has been demonstrated in experimental models of mastitis (an infection of the mammary gland that commonly affects both animals and women). In these models, the new treatment proved to be as effective as vancomycin, one of the most powerful antibiotics currently available for treating infections caused by Staphylococcus aureus.

Íñigo Lasa, who led the research, highlights the significance of this therapeutic approach:
“One of the major advantages of this strategy is its extremely high precision: it targets only Staphylococcus aureus at the site of infection without affecting the rest of the body's bacterial communities. This represents a key difference from conventional antibiotics, which generally act indiscriminately and also destroy bacteria that perform essential functions for human health.”

A Global Clinical Threat

The World Health Organization (WHO) considers Staphylococcus aureus one of the major threats to global public health because of its remarkable ability to evade conventional treatments. One of the bacterium’s greatest dangers is its capacity to adhere to surfaces and form biofilms: protective layers that can make it up to 1,000 times more resistant to antibiotics and immune-system defenses. Standard treatment typically relies on antibiotics such as vancomycin or daptomycin. However, when resistant strains emerge, therapeutic options can become severely limited.

Risk factors for developing serious Staphylococcus aureus infections include hospital surgeries, medical implants, open wounds, trauma, chronic diseases, and weakened immune systems. In maternal and child health as well as veterinary medicine, the bacterium is also associated with mastitis during breastfeeding.

Another reason why Staphylococcus aureus infections are becoming increasingly common is the ageing population and the growing use of prosthetic devices and implants. In such cases, the bacterium can colonize the implant surface and cause chronic infections that are often resolved only through the removal of the contaminated prosthesis and its replacement with a new one.

This newly identified mechanism will enable the study of novel therapeutic approaches for patients who do not respond to conventional immunotherapies, paving the way for more personalized and precise medicine.

Researchers from the Oncoimmunology Unit at the biomedical research center Navarrabiomed have identified a new molecular signalling pathway involving the interaction between the molecules PD-1, LAG-3, and MYC that impairs the proper functioning of the immune system in cancer patients, leading to resistance to conventional immunotherapy treatments. This discovery opens new avenues for the development of therapeutic strategies aimed at overcoming resistance to cancer immunotherapies.

The research, recently published in the high-impact scientific journal Signal Transduction and Targeted Therapy, was led by Drs. Luisa Chocarro, David Escors, and Grazyna Kochan.

New Molecular Pathways

The immunotherapies currently administered in hospitals are biological treatments designed to activate the immune system of cancer patients, enhancing the body's natural defenses to fight tumors. However, some patients do not respond to these treatments because their immune systems fail to function properly and develop mechanisms of therapeutic resistance. This resistance is frequently associated with the expression of LAG-3 on lymphocytes, a type of immune cell, and is considered one of the most important mechanisms underlying resistance to conventional immunotherapies. In this Navarrabiomed study, researchers applied high-throughput technologies to investigate how LAG-3 functions at the molecular level in immune-system lymphocytes in cancer.

For the first time, the study provides a detailed characterization of how LAG-3 operates both independently and in combination with PD-1 to inactivate lymphocytes. Specifically, the researchers discovered that the molecular cooperation between LAG-3 and PD-1 is regulated through the inhibition of MYC, another molecule of major importance in cancer biology. This inhibition causes lymphocytes to lose their ability to effectively recognize and eliminate cancer cells. The role of MYC inhibition was validated in tumor-infiltrating lymphocytes expressing PD-1 and LAG-3, as well as through the analysis of public genomic datasets from more than 500 cancer patients.

This research proposes, for the first time, a novel molecular pathway explaining why lymphocytes fail to destroy tumors. The findings also provide the foundation for future studies at Navarrabiomed aimed at further exploring these molecular mechanisms and developing new therapies to counteract them.

Dissemination of Results and Funding

The research was conducted in close collaboration with Navarrabiomed’s Proteomics Scientific-Technical Service and was made possible through funding from the Spanish Association Against Cancer (AECC), the Carlos III Health Institute (ISCIII), the Government of Navarre, and the European Union.

In addition to the recently published article, the findings were presented in 2025 at the ESMO Molecular Analysis for Precision Oncology (MAP) Congress, organized by the European Society for Medical Oncology (ESMO) in Paris.

• The publication compiles the current reference protocols available to support a more personalized and precise clinical management of the disease.

Esophageal cancer is a malignancy arising from the cells lining the inner mucosal surface of the esophagus, the part of the digestive tract that connects the throat to the stomach. It is considered an aggressive disease and ranks as the seventh leading cause of cancer-related death worldwide. Maria Alsina, Medical Oncologist at Navarra University Hospital (HUN) and Principal Investigator of the Translational Medical Oncology Unit at Navarrabiomed, specializing in the treatment of patients with esophagogastric cancers, has led the publication of the “SEOM-GEMCAD-TTD Clinical Guidelines for Esophageal Cancer 2025” in the international open-access journal Clinical and Translational Oncology.

The publication updates the clinical care protocols for the management of esophageal cancer in Spain and serves as a reference guideline for medical oncologists across Spanish hospitals. It provides a comprehensive summary of the current scientific evidence regarding the diagnosis and therapeutic options available for this type of cancer.

Esophageal cancer is a highly lethal disease that requires a multidisciplinary approach. The guideline includes the latest developments in chemotherapy treatment for patients eligible for surgery, as well as the incorporation of targeted therapies, including immunotherapy, in more advanced stages of the disease. “The introduction of these changes has had a positive impact, improving survival outcomes for patients with esophageal cancer,” says Maria Alsina.

The guideline was developed under the leadership of the Spanish Society of Medical Oncology (SEOM), in collaboration with the Digestive Tumor Treatment Group (TTD) and the Spanish Multidisciplinary Group for Digestive Cancer (GEMCAD). Co-led by Dr. Maria Alsina and Dr. Ana Fernández-Montes from the University Hospital Complex of Ourense, the guideline also involved specialists from several leading Spanish healthcare institutions, including:

•    Regional University Hospital of Málaga
•    La Paz University Hospital
•    Virgen de la Salud Hospital
•    Elche General University Hospital
•    12 de Octubre University Hospital
•    Marqués de Valdecilla University Hospital

Read the full press release.

The doctoral research was carried out at the Translational Cardiology Unit of Navarrabiomed.

Biochemist Mattie Garaikoetxea Zubillaga has explored several aspects of chronic aortic regurgitation in his doctoral thesis, defended at the Public University of Navarre (UPNA). Chronic aortic regurgitation is a degenerative cardiovascular disease characterized by the inadequate closure of the aortic valve and occurs more frequently in men. Specifically, his research examined, on the one hand, sex-related differences in valvular interstitial and endothelial cells, and on the other, the potential benefits of mineralocorticoid receptor antagonism, a type of pharmacological treatment.
The research was conducted at the Translational Cardiology Unit of Navarrabiomed under the supervision of Natalia López Andrés, principal investigator of the unit, and Eva Jover García, head of the unit’s Arrhythmias research line.

As noted, chronic aortic regurgitation is a degenerative cardiovascular disease defined by the inadequate sealing of the aortic valve, resulting in an abnormal backward flow of blood from the aorta into the left ventricle of the heart. The prevalence of its most severe form is estimated at 1.6% of the Western population over the age of 65, and it is diagnosed three times more frequently in men.

Currently, there is no effective pharmacological treatment capable of slowing, halting, let alone reversing the disease. As a result, progression toward heart failure can only be prevented through surgery. “These interventions entail significant economic and socio-healthcare costs, making it essential to identify new therapeutic targets and effective drugs that could prevent disease progression,” explains the researcher.

Against this backdrop, the doctoral thesis had a dual objective. First, to analyze sex-related differences at the molecular and cellular level, considering the marked disparity in disease prevalence between men and women. Second, to investigate the role of the mineralocorticoid receptor protein in the development of the disease and assess its pharmacological blockade as a potential therapeutic strategy.

The study included a cohort of 144 patients, who donated serum samples and aortic valve tissue following surgery. “Using this tissue, we were able to analyze both gene and protein expression in the cells that make up the aortic valve, namely valvular interstitial cells and valvular endothelial cells,” explains the author.

Differences Between Men and Women

The findings showed that valvular interstitial cells from men and women undergoing surgery for chronic aortic regurgitation differ significantly. “Cells from male patients are more prone to developing fibrotic and inflammatory processes, whereas cells from female patients appear to be healthier,” the researcher notes. “The role of valvular endothelial cells was also examined, although sex-related differences were much more limited,” he adds.

The thesis further demonstrated that the mineralocorticoid receptor is present in the aortic valves of patients with chronic aortic regurgitation, with higher expression levels observed in male patients. Moreover, receptor expression was associated with increased levels of both inflammatory and fibrotic mediators. In other cardiovascular diseases, pharmacological blockade of this receptor, using drugs already employed in routine clinical practice in Spanish hospitals, has yielded substantial clinical benefits. “In line with these findings, we demonstrated that, at both the cellular and molecular levels, blocking this receptor prevents the pro-fibrotic and pro-inflammatory effects of its activation, processes that are associated with the development of aortic regurgitation,” explains Garaikoetxea. “Furthermore, aortic valves from patients who were receiving this type of medication for other conditions showed lower expression of inflammatory and fibrotic markers.”

Overall, the research has demonstrated for the first time that, at the cellular level, men exhibit greater activation of fibrotic and inflammatory pathways, as well as higher mineralocorticoid receptor expression, in the context of chronic aortic regurgitation. By contrast, cells from women display less pronounced or comparatively healthier processes, suggesting differences in the disease’s pathophysiology and progression between sexes. “The clinical implications of the sexual dimorphism currently observed in this disease will be investigated in future studies by our research group,” says Mattie Garaikoetxea.

“Finally, molecular-level benefits of mineralocorticoid receptor antagonism have been observed, opening the door to future studies that could confirm the therapeutic value of these drugs in chronic aortic regurgitation and potentially support their repositioning for this indication,” he concludes.

Brief CV of Mattie Garaikoetxea

Mattie Garaikoetxea holds a Bachelor’s Degree in Biochemistry from the University of Navarra and a Master’s Degree in Health Sciences Research from UPNA. He received a Navarrabiomed fellowship to carry out his doctoral research. The results of his work were recently presented at the Heart Valve Society Annual Meeting 2025 in Cairo, Egypt, under the title “Sex Differences in Aortic Valve Inflammation and Remodeling in Chronic Severe Aortic Regurgitation.” During his PhD, he also completed a research stay at the Centre de Recherche des Cordeliers in Paris.

He is the author of 17 scientific articles published in international journals and has presented research at around 30 national and international medical conferences. In addition, he has participated in six research projects funded by IdiSNA or Navarrabiomed.

Con fecha 19 de diciembre de 2025 se ha publicado la resolución definitiva de los Programas de Ayudas de Navarrabiomed 2025.

La Unidad de Gestión de la Investigación junto con el Comité Científico Interno, la Comisión de Evaluación y Seguimiento y el Panel de Evaluación de Navarrabiomed, tras evaluar los criterios de valoración establecidos en las bases reguladoras de las ayudas postdoctoral, predoctoral, predoctoral en el área de dimensión de género y MCVM de Navarrabiomed 2025, publica la adjudicación definitiva de los Programas de Ayudas de Navarrabiomed 2025.

A continuación, se facilita la documentación relacionada:

●    Permitirá simular la atención profesional en suturas, biopsias y venopunción 

Navarrabiomed – Fundación Miguel Servet y el Hospital Universitario de Navarra han firmado un convenio de colaboración con la empresa navarra Ysium Medical que permitirá la implantación en el SNS-O de dispositivos médico-quirúrgicos innovadores. Los desarrollos permitirán a los y las profesionales formarse y ensayar técnicas sanitarias como suturas, biopsias y venopunción, entre otros, previo a la realización de dichos procedimientos a pacientes. 

La Unidad de Innovación de Navarrabiomed y del Departamento de Salud tiene como objetivo promover, apoyar y canalizar las ideas e iniciativas de innovación procedentes del sistema público navarro de Salud. En este sentido, el convenio ahora firmado pretende optimizar y mejorar los procesos del ámbito sanitario, así como promover la docencia y adiestramiento de los y las profesionales con mayor realismo y detalle antes de la realización. 
 

Validación de kits de simulación 

Los nuevos desarrollos facilitarán innovadores kits de simulación para la práctica de suturas (cara y brazo), biopsias (seno, piel y médula ósea del esternón) y venopunción. Para su validación, Navarrabiomed coordina un grupo de trabajo que cuenta con la participación activa de profesionales de diversos Servicios y Unidades del Hospital Universitario de Navarra. 
Por el momento, se han celebrado varios encuentros para certificar la calidad, usabilidad y eficacia de los desarrollos y se prevé que los dispositivos finales acordados se implanten en el HUN en el segundo semestre de 2024.  
 

• El encuentro ha dado a conocer casos de éxito en los que se han involucrado profesionales del HUN, UPNA y Navarrabiomed. 

La Unidad de Innovación de Navarrabiomed - Fundación Miguel Servet organizó la mesa redonda “Y ahora, ¿qué hago con mi investigación?” el pasado jueves, 12 de diciembre con el objetivo de abordar cómo a partir de una idea, una invención, ésta puede valorizarse, protegerse y llegar a mercado. En el encuentro intervinieron Beatriz Pérez y Marina Galilea, responsable y asesora legal de la Unidad de Innovación, respectivamente, y tres profesionales del ámbito sanitario, universitario e investigador. 

En primer lugar, Gonzalo Alonso, cardiólogo del Hospital Universitario de Navarra, intervino para dar a conocer su experiencia en protección de la innovación como inventor en una patente de asistencia ventricular para pacientes con insuficiencia cardiaca y el estado actual del proceso para licenciarla a una empresa, fase en la que está siendo asesorado por el equipo de Innovación de Navarrabiomed. 

Para dar a conocer la protección y transferencia tecnológica al mercado en el ámbito universitario participó Iñaki Casado, Jefe de la Sección de Transferencia de conocimiento de la Universidad Pública de Navarra, que expuso cuatro casos de éxito de diversa tipología y temática.   

Por último, los asistentes conocieron el caso de Leyre Ruete, co-fundadora y CEO de la empresa Eversens, una spin-off de la UPNA creada en 2015 a partir de desarrollos surgidos en el ámbito investigador, que contaron con la colaboración del Hospital Universitario de Navarra y Navarrabiomed. En la actualidad diseñan, desarrollan, fabrican y comercializan soluciones de análisis de la respiración humana para detectar, de forma no invasiva, biomarcadores exhalados útiles para el diagnóstico y monitorización de diversas enfermedades.

Los tres testimonios pusieron de manifiesto la importancia que tiene la protección en el proceso de transferencia tecnológica. En concreto, incidieron en cómo antes de difundir cualquier resultado de investigación se debe reflexionar y buscar asesoramiento externo para tener en cuenta el marco regulatorio y establecer la forma más adecuada de proteger y explotar los hallazgos obtenidos. 
 

• Más información y contacto Unidad de Innovación Navarrabiomed-FMS.